| | Mean | SD | Median | Range |
|---|
Age (years) | 71.3 | 7.5 | 72 | 52–82 |
Days PSMA-PET to MRI | 50.2 | 32.5 | 42 | 1–110 |
PI-RADS score | 4.7 | 0.6 | 5 | 3–5 |
Days GSc to PSMA-PET | 74.2 | 80.2 | 46 | 3–299 |
Gleason score | 7.9 | 1.1 | 8 | 6–10 |
Days PSA to PSMA-PET | 16.2 | 25.6 | 3 | 0–84 |
PSA (ng/ml) | 17.7 | 21.5 | 11 | 0.23–116 |
VTV (cm3) | 12.3 | 11.3 | 9 | 0.8–54.1 |
- This table summarizes the main characteristics of the patients investigated in this study. This included the age of the patients, the PI-RADS and Gleason score, PSA blood level, and the viable tumor volume as well as the time difference between PSMA-PET and MRI, between Gleason score and PSMA-PET, between PSA blood level sampling date and PSMA-PET. Data are given in means, standard deviations, medians, and ranges. Abbreviations: GSc Gleason score, PSA prostate-specific antigen blood level, PSMA prostate-specific membrane antigen, PET positron emission tomography, MRI magnetic resonance imaging, PI-RADS prostate imaging reporting and data system, VTV viable tumor volume
